The Prognostic Role of Macrophage Polarization in the Colorectal Cancer Microenvironment.


Journal

Cancer immunology research
ISSN: 2326-6074
Titre abrégé: Cancer Immunol Res
Pays: United States
ID NLM: 101614637

Informations de publication

Date de publication:
01 2021
Historique:
received: 19 06 2020
revised: 13 08 2020
accepted: 29 09 2020
pubmed: 8 10 2020
medline: 21 10 2021
entrez: 7 10 2020
Statut: ppublish

Résumé

Macrophages are among the most common cells in the colorectal cancer microenvironment, but their prognostic significance is incompletely understood. Using multiplexed immunofluorescence for CD68, CD86, IRF5, MAF, MRC1 (CD206), and KRT (cytokeratins) combined with digital image analysis and machine learning, we assessed the polarization spectrum of tumor-associated macrophages in 931 colorectal carcinomas. We then applied Cox proportional hazards regression to assess prognostic survival associations of intraepithelial and stromal densities of M1-like and M2-like macrophages while controlling for potential confounders, including stage and microsatellite instability status. We found that high tumor stromal density of M2-like macrophages was associated with worse cancer-specific survival, whereas tumor stromal density of M1-like macrophages was not significantly associated with better cancer-specific survival. High M1:M2 density ratio in tumor stroma was associated with better cancer-specific survival. Overall macrophage densities in tumor intraepithelial or stromal regions were not prognostic. These findings suggested that macrophage polarization state, rather than their overall density, was associated with cancer-specific survival, with M1- and M2-like macrophage phenotypes exhibiting distinct prognostic roles. These results highlight the utility of a multimarker strategy to assess the macrophage polarization at single-cell resolution within the tumor microenvironment.

Identifiants

pubmed: 33023967
pii: 2326-6066.CIR-20-0527
doi: 10.1158/2326-6066.CIR-20-0527
pmc: PMC7785652
mid: NIHMS1635603
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

8-19

Subventions

Organisme : NCI NIH HHS
ID : R35 CA197735
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA118553
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA167552
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA137178
Pays : United States
Organisme : NIDDK NIH HHS
ID : K24 DK098311
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA186107
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA169141
Pays : United States
Organisme : NCI NIH HHS
ID : R03 CA197879
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA167552
Pays : United States
Organisme : Cancer Research UK
ID : UK C10674/A27140
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R35 CA253185
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA127003
Pays : United States
Organisme : NCI NIH HHS
ID : K07 CA190673
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA222940
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA230873
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA087969
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA055075
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA151993
Pays : United States

Informations de copyright

©2020 American Association for Cancer Research.

Références

Br J Cancer. 2019 Apr;120(9):871-882
pubmed: 30936499
Annu Rev Immunol. 2019 Apr 26;37:269-293
pubmed: 30649988
Neoplasia. 2008 Jun;10(6):534-41
pubmed: 18516290
Nat Immunol. 2016 Jan;17(1):34-40
pubmed: 26681460
J Mol Diagn. 2008 Jan;10(1):13-27
pubmed: 18165277
Int J Cancer. 2012 Aug 15;131(4):864-73
pubmed: 21952788
J Leukoc Biol. 2012 Dec;92(6):1177-86
pubmed: 22966131
Immunity. 2019 Jul 16;51(1):15-26
pubmed: 31315033
Eur J Epidemiol. 2018 Apr;33(4):381-392
pubmed: 29264788
Clin Cancer Res. 2020 Aug 15;26(16):4326-4338
pubmed: 32439699
Sci Rep. 2017 Oct 17;7(1):13380
pubmed: 29042640
Cancer Treat Rev. 2020 Feb;83:101949
pubmed: 31869737
Br J Cancer. 2017 Nov 21;117(11):1583-1591
pubmed: 29065107
Sci Rep. 2017 Jan 06;7:40144
pubmed: 28057928
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
Nat Immunol. 2011 Mar;12(3):231-8
pubmed: 21240265
Cancer Immunol Res. 2019 Aug;7(8):1230-1236
pubmed: 31217164
Sci Rep. 2017 Dec 1;7(1):16717
pubmed: 29196718
Circulation. 1992 Nov;86(5):1475-84
pubmed: 1330360
World J Gastroenterol. 2019 Aug 21;25(31):4383-4404
pubmed: 31496619
J Histochem Cytochem. 2007 Jun;55(6):545-54
pubmed: 17242468
Cancers (Basel). 2019 Feb 20;11(2):
pubmed: 30791580
N Engl J Med. 2007 May 24;356(21):2131-42
pubmed: 17522398
Cancer Discov. 2018 Jun;8(6):730-749
pubmed: 29510987
J Mol Diagn. 2007 Jul;9(3):305-14
pubmed: 17591929
Annu Rev Physiol. 2017 Feb 10;79:541-566
pubmed: 27813830
Immunity. 2017 Aug 15;47(2):235-250.e4
pubmed: 28813657
Clin Cancer Res. 2007 Mar 1;13(5):1472-9
pubmed: 17332291
Histopathology. 2018 Oct;73(4):663-671
pubmed: 29906313
Cancer Res. 2018 Oct 1;78(19):5492-5503
pubmed: 30206177
Gut. 2012 Jun;61(6):847-54
pubmed: 22427238
Int Rev Cell Mol Biol. 2019;342:73-93
pubmed: 30635094
Int J Cancer. 2016 Jul 1;139(1):112-21
pubmed: 26874795
Br J Cancer. 2020 Apr;122(9):1367-1377
pubmed: 32157241
Br J Cancer. 2013 Aug 20;109(4):1013-22
pubmed: 23868006
Immunity. 2014 Jul 17;41(1):14-20
pubmed: 25035950
Gut. 2018 Jun;67(6):1168-1180
pubmed: 29437869
Immunity. 2014 Feb 20;40(2):274-88
pubmed: 24530056
Oncoimmunology. 2015 Nov 9;5(4):e1106677
pubmed: 27141391
Eur J Cancer. 2013 Oct;49(15):3320-34
pubmed: 23810249
J Mol Diagn. 2005 Aug;7(3):413-21
pubmed: 16049314
J Womens Health. 1997 Feb;6(1):49-62
pubmed: 9065374
J Immunol. 2005 Mar 15;174(6):3484-92
pubmed: 15749884
PLoS One. 2012;7(10):e47045
pubmed: 23077543
Trends Mol Med. 2018 May;24(5):472-489
pubmed: 29655673
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
PLoS One. 2013 Nov 15;8(11):e80908
pubmed: 24260507
Nat Immunol. 2010 Oct;11(10):889-96
pubmed: 20856220
Oncoimmunology. 2017 Jul 12;6(12):e1342918
pubmed: 29209561
Clin Cancer Res. 2019 Jul 1;25(13):3896-3907
pubmed: 30988081
Cancer Sci. 2013 Apr;104(4):437-44
pubmed: 23298232
Nat Hum Behav. 2018 Jan;2(1):6-10
pubmed: 30980045

Auteurs

Juha P Väyrynen (JP)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Cancer and Translational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital, and University of Oulu, Oulu, Finland.

Koichiro Haruki (K)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.

Mai Chan Lau (MC)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Sara A Väyrynen (SA)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.

Rong Zhong (R)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Andressa Dias Costa (A)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.

Jennifer Borowsky (J)

Conjoint Gastroenterology Department, QIMR Berghofer Medical Research Institute, Queensland, Australia.

Melissa Zhao (M)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Kenji Fujiyoshi (K)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Kota Arima (K)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Tyler S Twombly (TS)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Junko Kishikawa (J)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Simeng Gu (S)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Saina Aminmozaffari (S)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Shanshan Shi (S)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Yoshifumi Baba (Y)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Naohiko Akimoto (N)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Tomotaka Ugai (T)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Annacarolina Da Silva (A)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Jennifer L Guerriero (JL)

Breast Tumor Immunology Laboratory, Dana-Farber Cancer Institute, Boston, Massachusetts.
Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts.

Mingyang Song (M)

Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts.

Kana Wu (K)

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Andrew T Chan (AT)

Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts.
Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Reiko Nishihara (R)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Charles S Fuchs (CS)

Yale Cancer Center, New Haven, Connecticut.
Department of Medicine, Yale School of Medicine, New Haven, Connecticut.
Smilow Cancer Hospital, New Haven, Connecticut.

Jeffrey A Meyerhardt (JA)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.

Marios Giannakis (M)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Shuji Ogino (S)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. janowak@bwh.harvard.edu sogino@bwh.harvard.edu.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
Cancer Immunology and Cancer Epidemiology Programs, Dana-Farber/Harvard Cancer Center, Boston, Massachusetts.

Jonathan A Nowak (JA)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. janowak@bwh.harvard.edu sogino@bwh.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH